Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 632

1.

Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration.

Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, Abarca-Zabalía J, Susmozas-Sánchez A, González Lafuente L, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Ruilope LM, Ruiz-Hurtado G.

Nutrients. 2019 Nov 17;11(11). pii: E2809. doi: 10.3390/nu11112809.

2.

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators.

Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30.

3.

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators.

Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.

4.

Resistant hypertension: new insights and therapeutic perspectives.

Ruilope LM, Rodríguez-Sánchez E, Navarro-García JA, Segura J, Órtiz A, Lucia A, Ruiz-Hurtado G.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 9. pii: pvz057. doi: 10.1093/ehjcvp/pvz057. [Epub ahead of print]

PMID:
31598644
5.

The endless story of markers of renal function and cardiovascular risk.

Ruilope LM, Rodríguez-Sánchez E, Ruiz-Hurtado G.

Eur Heart J. 2019 Nov 1;40(42):3494-3495. doi: 10.1093/eurheartj/ehz489. No abstract available.

PMID:
31386142
6.

Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors.

RodrÍguez-SÁnchez E, Navarro-GarcÍa JA, Aceves-Ripoll J, GonzÁlez-Lafuente L, Corbacho-Alonso N, Martinez P, Calvo-Bonacho E, Alvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G.

Transl Res. 2019 Oct;212:54-66. doi: 10.1016/j.trsl.2019.06.002. Epub 2019 Jun 29.

PMID:
31295436
7.

Proteomic investigations into hypertension: what's new and how might it affect clinical practice?

Corbacho-Alonso N, Rodríguez-Sánchez E, Martin-Rojas T, Mouriño-Alvarez L, Sastre-Oliva T, Hernandez-Fernandez G, Padial LR, Ruilope LM, Ruiz-Hurtado G, Barderas MG.

Expert Rev Proteomics. 2019 Jul;16(7):583-591. doi: 10.1080/14789450.2019.1632197. Epub 2019 Jun 20.

PMID:
31195841
8.

[Position statement on ambulatory blood pressure monitoring (ABPM) by the Spanish Society of Hypertension (2019)].

Gijón-Conde T, Gorostidi M, Banegas JR, de la Sierra A, Segura J, Vinyoles E, Divisón-Garrote JA, Ruilope LM.

Hipertens Riesgo Vasc. 2019 Oct - Dec;36(4):199-212. doi: 10.1016/j.hipert.2019.05.002. Epub 2019 Jun 6. Spanish.

9.

Monotherapy still useful in a bunch of patients with arterial hypertension.

Ruilope LM, Ruiz-Hurtado G.

Int J Cardiol. 2019 Sep 15;291:119-120. doi: 10.1016/j.ijcard.2019.05.057. Epub 2019 May 24. No abstract available.

PMID:
31155327
10.

Impact of the new USA and ESC/ESH HTN guidelines for Spain.

Ruilope LM, Ruiz-Hurtado G.

Eur Heart J. 2019 Jun 1;40(21):1660-1661. doi: 10.1093/eurheartj/ehz345. No abstract available.

PMID:
31152547
11.

Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals.

Ruilope LM, Ruiz-Hurtado G, Barderas MG, de la Cruz JJ, Lucia A, de la Sierra A, Gorostidi M, Vinyoles E, Segura J, Solís J, Arribas F, García-Puig J, Tamargo J, O'Brien E, Volpe M, Whelton PK, Williams B, Banegas JR.

Hypertension. 2019 Jul;74(1):130-136. doi: 10.1161/HYPERTENSIONAHA.119.12921. Epub 2019 May 28.

PMID:
31132953
12.

May Measurement Month 2017: an analysis of blood pressure screening in Spain-Europe.

Molinero A, Ruilope LM, Tous S, Fornos JA, Mera I, Andrés NF, Iracheta M, Xia X, Beaney T, Poulter NR, Rodilla E, Martínez F, Gijón-Conde T.

Eur Heart J Suppl. 2019 Apr;21(Suppl D):D107-D110. doi: 10.1093/eurheartj/suz070. Epub 2019 Apr 24.

13.

Estimating the impact of obesity and metabolic phenotype on sickness absence. Results from the ICARIA study.

Catalina-Romero C, Sanchez Chaparro MA, Valdivielso P, Quevedo-Aguado L, Brotons C, Ruilope LM, Calvo-Bonacho E.

Nutr Metab Cardiovasc Dis. 2019 Apr;29(4):383-389. doi: 10.1016/j.numecd.2018.12.005. Epub 2018 Dec 27.

PMID:
30803866
14.

Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension.

Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Lopez JA, Minguez P, Santiago-Hernandez A, Vazquez J, Segura J, Ruiz-Hurtado G, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G.

Hypertension. 2019 Apr;73(4):794-802. doi: 10.1161/HYPERTENSIONAHA.118.12242.

PMID:
30712426
15.

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention.

Martínez PJ, Baldán-Martín M, López JA, Martín-Lorenzo M, Santiago-Hernández A, Agudiez M, Cabrera M, Calvo E, Vázquez J, Ruiz-Hurtado G, Vivanco F, Ruilope LM, Barderas MG, Alvarez-Llamas G.

Atherosclerosis. 2019 Mar;282:67-74. doi: 10.1016/j.atherosclerosis.2019.01.003. Epub 2019 Jan 14.

PMID:
30690299
16.

Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes.

Navarro-García JA, Delgado C, Fernández-Velasco M, Val-Blasco A, Rodríguez-Sánchez E, Aceves-Ripoll J, Gómez-Hurtado N, Bada-Bosch T, Mérida-Herrero E, Hernández E, Praga M, Salguero R, Solís J, Arribas F, Delgado JF, Bueno H, Kuro-O M, Ruilope LM, Ruiz-Hurtado G.

Nephrol Dial Transplant. 2019 Nov 1;34(11):1864-1875. doi: 10.1093/ndt/gfy392.

PMID:
30629224
17.

New vascular biomarkers related to ABPM phenotypes in untreated patients.

Ruilope LM, Ruiz-Hurtado G.

J Clin Hypertens (Greenwich). 2019 Jan;21(1):53-54. doi: 10.1111/jch.13445. Epub 2018 Dec 7. No abstract available.

18.

Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients.

Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, Álvarez-Llamas G, Segura J, Barderas MG, Ruilope LM, Ruiz-Hurtado G.

Nefrologia. 2019 Mar - Apr;39(2):184-191. doi: 10.1016/j.nefro.2018.08.009. Epub 2018 Dec 1. English, Spanish.

19.

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.

González-Blázquez R, Somoza B, Gil-Ortega M, Martín Ramos M, Ramiro-Cortijo D, Vega-Martín E, Schulz A, Ruilope LM, Kolkhof P, Kreutz R, Fernández-Alfonso MS.

Front Pharmacol. 2018 Oct 9;9:1131. doi: 10.3389/fphar.2018.01131. eCollection 2018.

20.

Prognostic Value of Masked Uncontrolled Hypertension.

Pierdomenico SD, Pierdomenico AM, Coccina F, Clement DL, De Buyzere ML, De Bacquer DA, Ben-Dov IZ, Vongpatanasin W, Banegas JR, Ruilope LM, Thijs L, Staessen JA.

Hypertension. 2018 Oct;72(4):862-869. doi: 10.1161/HYPERTENSIONAHA.118.11499.

21.

Ambulatory Blood Pressure and Mortality.

Banegas JR, Ruilope LM, Williams B.

N Engl J Med. 2018 Sep 27;379(13):1287-8. doi: 10.1056/NEJMc1809851. No abstract available.

PMID:
30257163
22.

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G; ARRIVE Executive Committee.

Lancet. 2018 Sep 22;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26.

PMID:
30158069
23.

Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors.

Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O, Zugaza JL, Izquierdo M, Ruilope LM, Lucia A.

Nat Rev Cardiol. 2018 Dec;15(12):731-743. doi: 10.1038/s41569-018-0065-1. Review.

PMID:
30115967
24.

The epidemiological magnitude of white-coat hypertension and masked hypertension in Africa.

Banegas JR, Ruilope LM.

J Clin Hypertens (Greenwich). 2018 Jul 9. doi: 10.1111/jch.13328. [Epub ahead of print] No abstract available.

25.

Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factors.

Gorostidi M, Sánchez-Martínez M, Ruilope LM, Graciani A, de la Cruz JJ, Santamaría R, Del Pino MD, Guallar-Castillón P, de Álvaro F, Rodríguez-Artalejo F, Banegas JR.

Nefrologia. 2018 Nov - Dec;38(6):606-615. doi: 10.1016/j.nefro.2018.04.004. Epub 2018 Jun 18. English, Spanish.

26.

[Mortality study from the Spanish Registry of ABPM. An appeal for the transition of ABPM to clinical practice].

Banegas JR, Ruilope LM.

Hipertens Riesgo Vasc. 2018 Jun 13. pii: S1889-1837(18)30063-1. doi: 10.1016/j.hipert.2018.05.002. [Epub ahead of print] Spanish. No abstract available.

PMID:
29908924
27.

Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mm Hg.

de la Sierra A, Banegas JR, Vinyoles E, Segura J, Gorostidi M, de la Cruz JJ, Ruilope LM.

Circulation. 2018 Jun 12;137(24):2651-2653. doi: 10.1161/CIRCULATIONAHA.118.034619. Epub 2018 Apr 30. No abstract available.

PMID:
29712713
28.

[Spanish Society of Hypertension position statement on the 2017 ACC/AHA hypertension guidelines].

Gijón-Conde T, Gorostidi M, Camafort M, Abad-Cardiel M, Martín-Rioboo E, Morales-Olivas F, Vinyoles E, Armario P, Banegas JR, Coca A, de la Sierra A, Martell-Claros N, Redón J, Ruilope LM, Segura J.

Hipertens Riesgo Vasc. 2018 Apr 24. pii: S1889-1837(18)30033-3. doi: 10.1016/j.hipert.2018.04.001. [Epub ahead of print] Spanish.

29.

Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality.

Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ, Ruiz-Hurtado G, Segura J, Rodríguez-Artalejo F, Williams B.

N Engl J Med. 2018 Apr 19;378(16):1509-1520. doi: 10.1056/NEJMoa1712231.

30.

Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression.

Baldan-Martin M, Rodríguez-Sánchez E, González-Calero L, Ruilope LM, Alvarez-Llamas G, Barderas MG, Ruiz-Hurtado G.

Clin Sci (Lond). 2018 Apr 6;132(7):739-758. doi: 10.1042/CS20180097. Print 2018 Apr 16. Review.

PMID:
29626149
31.

White-coat UnControlled Hypertension, Masked UnControlled Hypertension, and True UnControlled Hypertension, phonetic and mnemonic terms for treated hypertension phenotypes.

Banegas JR, Ruilope LM, Williams B.

J Hypertens. 2018 Feb;36(2):446-447. doi: 10.1097/HJH.0000000000001615. No abstract available.

PMID:
29611838
32.

Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.

de la Sierra A, Armario P, Oliveras A, Banegas JR, Gorostidi M, Vinyoles E, de la Cruz JJ, Segura J, Ruilope LM.

J Hypertens. 2018 Jul;36(7):1563-1570. doi: 10.1097/HJH.0000000000001729.

PMID:
29601411
33.

Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.

Baldan-Martin M, Lopez JA, Corbacho-Alonso N, Martinez PJ, Rodriguez-Sanchez E, Mourino-Alvarez L, Sastre-Oliva T, Martin-Rojas T, Rincón R, Calvo E, Vazquez J, Vivanco F, Padial LR, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG.

Sci Rep. 2018 Mar 19;8(1):4802. doi: 10.1038/s41598-018-23037-7.

34.

Author Correction: Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria.

Martin-Lorenzo M, Gonzalez-Calero L, Martinez PJ, Baldan-Martin M, Lopez JA, Ruiz-Hurtado G, de la Cuesta F, Segura J, Vazquez J, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G.

Sci Rep. 2018 Mar 2;8(1):4154. doi: 10.1038/s41598-018-22185-0.

35.

Blood pressure variability increases with advancing chronic kidney disease stage: a cross-sectional analysis of 16 546 hypertensive patients.

Sarafidis PA, Ruilope LM, Loutradis C, Gorostidi M, de la Sierra A, de la Cruz JJ, Vinyoles E, Divisón-Garrote JA, Segura J, Banegas JR.

J Hypertens. 2018 May;36(5):1076-1085. doi: 10.1097/HJH.0000000000001670.

PMID:
29465710
36.

The use of antihypertensive fixed combinations in clinical practice needs a reappraisal.

Ruilope LM, Banegas JR.

J Clin Hypertens (Greenwich). 2018 Apr;20(4):716-717. doi: 10.1111/jch.13244. Epub 2018 Feb 19. No abstract available.

37.

PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology.

Navarro-García JA, Fernández-Velasco M, Delgado C, Delgado JF, Kuro-O M, Ruilope LM, Ruiz-Hurtado G.

Eur J Clin Invest. 2018 Apr;48(4). doi: 10.1111/eci.12902. Epub 2018 Feb 21. Review.

PMID:
29394451
38.

Obesity and hypertension in Latin America: Current perspectives.

Ruilope LM, Nunes Filho ACB, Nadruz W Jr, Rodríguez Rosales FF, Verdejo-Paris J.

Hipertens Riesgo Vasc. 2018 Apr - Jun;35(2):70-76. doi: 10.1016/j.hipert.2017.12.004. Epub 2018 Feb 1. Review.

PMID:
29361428
39.

Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation.

Rodriguez-Padial L, Akerström F, Barderas MG, Vivanco F, Arias MA, Segura J, Ruilope LM.

Diseases. 2017 Dec 8;5(4). pii: E33. doi: 10.3390/diseases5040033.

40.

Frailty, Disability, and Ambulatory Blood Pressure in Older Adults.

Gijón-Conde T, Graciani A, López-García E, García-Esquinas E, Laclaustra M, Ruilope LM, Rodríguez-Artalejo F, Banegas JR.

J Am Med Dir Assoc. 2018 May;19(5):433-438. doi: 10.1016/j.jamda.2017.11.014. Epub 2017 Dec 30.

PMID:
29291959
41.

Prevalence and Clinical Characteristics of Refractory Hypertension.

Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope LM, Dudenbostel T, de la Sierra A.

J Am Heart Assoc. 2017 Dec 7;6(12). pii: e007365. doi: 10.1161/JAHA.117.007365.

42.

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.

Rossi GP, Seccia TM, Barton M, Danser AHJ, de Leeuw PW, Dhaun N, Rizzoni D, Rossignol P, Ruilope LM, van den Meiracker AH, Ito S, Hasebe N, Webb DJ.

J Hypertens. 2018 Mar;36(3):462-471. doi: 10.1097/HJH.0000000000001600. Review.

PMID:
29135628
43.

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension.

Rossi GP, Seccia TM, Barton M, Danser AHJ, de Leeuw PW, Dhaun N, Rizzoni D, Rossignol P, Ruilope LM, van den Meiracker AH, Ito S, Hasebe N, Webb DJ.

J Hypertens. 2018 Mar;36(3):451-461. doi: 10.1097/HJH.0000000000001599. Review.

PMID:
29120962
44.

Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension.

Ruiz-Hurtado G, Ruilope LM.

Eur Heart J. 2017 Nov 21;38(44):3318-3320. doi: 10.1093/eurheartj/ehx560. No abstract available.

PMID:
29059286
45.

Predictors for the development of microalbuminuria and interaction with renal function.

Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H.

J Hypertens. 2017 Dec;35(12):2501-2509. doi: 10.1097/HJH.0000000000001491.

PMID:
29035939
46.

Reply.

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, de Leeuw PW, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B.

J Hypertens. 2017 Nov;35(11):2327-2328. doi: 10.1097/HJH.0000000000001526. No abstract available.

47.

Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response.

Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Ruiz-Hurtado G, Prado JC, Segura J, de la Cuesta F, Barderas MG, Vivanco F, Ruilope LM, Alvarez-Llamas G.

Hypertension. 2017 Nov;70(5):1049-1056. doi: 10.1161/HYPERTENSIONAHA.117.09819. Epub 2017 Sep 5.

PMID:
28874460
48.

Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria.

Martin-Lorenzo M, Gonzalez-Calero L, Martinez PJ, Baldan-Martin M, Lopez JA, Ruiz-Hurtado G, de la Cuesta F, Segura J, Vazquez J, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G.

Sci Rep. 2017 Aug 21;7(1):8894. doi: 10.1038/s41598-017-09042-2. Erratum in: Sci Rep. 2018 Mar 2;8(1):4154.

49.

Blood pressure variability is increasing from the first to the second day of the interdialytic interval in hemodialysis patients.

Karpetas A, Loutradis C, Bikos A, Tzanis G, Koutroumpas G, Lazaridis AA, Mavromatidis K, Liakopoulos V, Papagianni A, Zebekakis P, Ruilope LM, Parati G, Sarafidis PA.

J Hypertens. 2017 Dec;35(12):2517-2526. doi: 10.1097/HJH.0000000000001478.

PMID:
28806350
50.

Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9-Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA.

Pulido-Olmo H, Rodríguez-Sánchez E, Navarro-García JA, Barderas MG, Álvarez-Llamas G, Segura J, Fernández-Alfonso M, Ruilope LM, Ruiz-Hurtado G.

Front Immunol. 2017 Jul 24;8:853. doi: 10.3389/fimmu.2017.00853. eCollection 2017.

Supplemental Content

Loading ...
Support Center